Funding the Next Wave in Women's Sexual Health
Semprae's senior executives, Mary Wallace Jaensch and Rachel Braun Scherl, partnered with Quaker Partners in 2008 to form Semprae Laboratories, Inc.
Quaker Partnures has been instrumental to Semprae's development and has been joined by Versant Ventures to invest behind Semprae's continuing growth
Quaker Partners: Company Profile
Established in 2003, Quaker Partners is a venture capital firm specializing in life science companies within the Mid-Atlantic region. The firm leads investments across the industry, spanning biopharmaceuticals, specialty pharmaceuticals, medical devices, human diagnostics and healthcare services.
Quaker Partners currently manages over $700 million in committed capital. Its investment team possesses extensive experience in venture capital, operational management and finance, as well as background in all sectors of the life science industry. Its portfolio includes businesses at all stages of development, from startups to publicly-held companies.
For more information about Quaker Partners extensive investment portfolio, visit www.quakerpartners.com.
VERSANT VENTURES: COMPANY PROFILE
Versant Ventures is a leading healthcare-focused venture capital firm specializing in early-stage investments in medical devices, biotechnology and pharmaceuticals, healthcare services, and healthcare information technology. The firm, founded in 1999, consists of a seasoned team of twelve managing directors with more than 130 years of venture capital investing experience and more than 150 years of operating experience.
Versant Ventures currently manages over $1.6 billion in committed capital having recently raised its fourth fund in July 2008, and is currently managing over 75 companies in its portfolio.
For more information about Versant Venture's extensive investment portfolio, visit www.versantventures.com.
Semprae Board of Directors
ADELE C. OLIVA
Adele Oliva joined Quaker Partners as a Partner in June 2007. Ms. Oliva spent the previous decade at Apax Partners where she was a partner and Co-Head of US Healthcare. Prior to joining Apax, Ms. Oliva held positions in marketing and business development with Baxter Healthcare's Cardiovascular and I.V. Systems divisions. Her current board responsibilities include a range of life science investments including: EKR Therapeutics, Oceana Therapeutics, Prometheus Labs, Semprae Laboratories and SkinMedica. Prior board responsibilities include ESP Pharma, Esprit Pharma and Xanodyne.
Camille Samuels is a managing partner of Versant Ventures, having joined in early 2000, shortly after its formation. Prior to joining Versant, Ms. Samuels was responsible for business development at Tularik, Inc. Before Tularik, Ms. Samuels worked in corporate development at Genzyme and Millennium Predictive Medicine. Ms. Samuels currently serves as a board member of the following companies: Achaogen, APT Pharmaceuticals, Kythera Biopharmaceuticals, and Transcept Pharmaceuticals, Inc. (TSPT), a public company.
Lucinda Holt is an accomplished technology CEO, currently leading Click Equations, a paid search management platform. She also co-founded and led anti-spam company TurnTide that she sold to Symantec, and was CEO of Destiny WebSolutions, an Internet technology company which she grew from $250,000 to $25m. She is currently a director of Monetate, Inc.
Stacie Mullen is SVP Marketing and Creative Services for Nutrisystems, Inc. Stacie joined Nutrisystem in 2005 to grow the celebrity marketing effort, spearheading the recruitment of celebrity talent including football legends Dan Marino and Coach Don Shula, and entertainer Marie Osmond. Stacie brings over 20 years of experience and expertise leading the creative development across all channels in an effort to continually develop and fortify brands.
MARY WALLACE JAENSCH
Mary Jaensch is the co-founder and CEO of Semprae Laboratories, the maker of Zestra®, the only patented, topical product clinically proven to increase feelings of arousal, desire and satisfaction for women. Prior to founding Semprae, Mary was an owner and principal of The Jannick Group, LLC/SPARK Solutions for Growth, consulting to Fortune 100 firms and leading consumer package good franchises.
RACHEL BRAUN SCHERL
Rachel Braun Scherl is the co-founder and President of Semprae Laboratories, the maker of Zestra®, the only patented, topical product clinically proven to increase feelings of arousal, desire and satisfaction for women. Prior to founding Semprae, Rachel was an owner and principal of The Jannick Group, LLC/SPARK Solutions for Growth, consulting to Fortune 100 firms and leading consumer package good franchises.
Contact us to learn about Semprae Laboratories, Inc.'s investment opportunities.